drugset / Trial / NCT05815758

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758

Phase 3 Completed 512 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.

Timeline

Start
2023-04-20
Primary completion
2023-09-18
Completion
2023-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.025 % Topical
Subject Ketotifen Small molecule 0.035 % Topical

Indications